This study showed that patients taking 75mg of Olpasiran previously every 12 weeks presented a 40–50% reduction in LP(a)
BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials
India will account for about 18% of the Asia-Pacific (APAC) MRI systems market in 2023
In March 2023, Japan’s Ministry of Health and Labor Welfare approved Novo Nordisk’s once-weekly subcutaneous glucagon-like peptide-1
CMOs showed an increasing reluctance to take on debt in 2022
Approval to dramatically change CAR-T therapies landscape
The positive safety review from the DSMB enables the trial to move forward as planned, with an estimated completion date in December 2023
Decisions on the marketing authorization for Rystiggo in the European and Japanese markets are expected in Q1 of 2024
Pfizer is likely to show GSK significant competition
The judicial response to industry lawsuits on drug pricing regulations have been mixed in the past
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
